In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 51 days of free consultation

 

Evolution of electrocardiographic abnormalities and arrhythmias in adult patients with beta thalassemia major during short-term follow-up

Session Poster session 1

Speaker Associate Professor Panagiotis Korantzopoulos

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P359

Authors : P Korantzopoulos (Ioannina,GR), M Kolios (Ioannina,GR), A Vlahos (Ioannina,GR)

15 views

Authors:
P Korantzopoulos1 , M Kolios1 , A Vlahos2 , 1University of Ioannina Medical School, First Department of Cardiology - Ioannina - Greece , 2University of Ioannina Medical School, Department of Pediatrics - Ioannina - Greece ,

Citation:

Background: Cardiac complications represent the major cause of mortality in patients with beta thalassemia major (TM). The arrhythmia burden is increased in TM even in patients without overt heart failure. In a previous study, we demonstrated that adult TM patients with preserved left ventricular systolic function have several baseline electrocardiographic abnormalities such as increased indexes of ventricular repolarization heterogeneity as well as attenuated indexes of cardiac autonomic function compared to control subjects.

Purpose: In this study, we aimed to examine the evolution of electrocardiographic abnormalities in a cohort of 47 patients with TM as well as the incidence of new-onset arrhythmias during a 12-month follow-up period.

Methods: We studied 47 adult TM patients (median age 36 [31-42] years, 57% men) without systolic heart failure. Baseline demographic and clinical characteristics were recorded while 12-lead electrocardiograms, 24-hour ECG Holter recordings, and treadmill exercise stress tests were analyzed at baseline and after 12 months in each patient. Classical electrocardiographic measurements (complexes duration and intervals), as well as novel indexes of depolarization and repolarization/dispersion of repolarization (QRS fragmentation; T peak-to-end; T peak-to-end/QT), were performed. Also, indexes of autonomic dysfunction, heart rate variability in Holter recordings, and heart rate recovery after exercise testing were assessed.

Results: Electrocardiographic indexes of atrial and ventricular depolarization and indexes of ventricular repolarization/dispersion of repolarization were not significantly changed during the short-term follow-up. The same was true with regard to indexes of autonomic imbalance. No significant variation was observed in paroxysmal atrial fibrillation (PAF) detection (4/47 at baseline vs. 8/47 at 12 months; p=0.32). However, 3/8 patients that were diagnosed with PAF at the second evaluation did not have the arrhythmia at the initial screening. Thus, in total 12/47 (25%) of TM patients had PAF while 1/3 of these events was silent.

Conclusions:  TM patients without overt heart failure exhibit electrocardiographic repolarization and autonomic dysfunction abnormalities that do not significantly alter during a short-term follow-up period. Of note, the AF burden in this population seems to be considerable. Undoubtedly, studies with a longer follow-up may elucidate the exact prognostic significance of specific electrocardiographic and arrhythmic parameters in this setting.

This content is currently on FREE ACCESS, enjoy another 51 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are